Overview
- The suit says Beta Bionics' stock plunged after a missed new‑patient starts metric triggered a roughly 37% one‑day drop on January 8–9, 2026 and fell again after the FDA warning letter went public on February 24, 2026.
- The FDA's warning letter faulted the company for failing to analyze complaint data, not implementing corrective and preventive actions, and not timely reporting serious injuries to the agency.
- Plaintiffs allege the company received thousands of iLet user complaints, including hundreds of life‑threatening hypoglycemic events that they say were tied to an aggressive insulin‑dosing algorithm and were not properly investigated or reported.
- The case, captioned Holtzman v. Beta Bionics and pending in the U.S. District Court for the Central District of California, covers purchases from July 30, 2025 through February 24, 2026 and has a November 3, 2026 deadline to move for appointment as lead plaintiff.
- Multiple national plaintiff firms are soliciting investors and investigating claims while the litigation is in its early stage with no class certified and no determinations of liability or remedies; the dispute could prompt further regulatory and whistleblower probes and shape investor recovery options.